Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,423 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Brain Neoplasms Clear all
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments

NCT01445314
View directory record Official record
Conditions
HIV, Brain Tumors, Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month and older
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas

NCT00002876
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, etoposide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2005
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Oct 20, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

NCT04278118
View directory record Official record
Conditions
Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm, Nerve Sheath Neoplasm, Pituitary Gland Adenoma, Schwannoma
Interventions
Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT00671710
View directory record Official record
Conditions
Brain Tumors
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
Advocate Hospital System
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2011 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

NCT00762255
View directory record Official record
Conditions
Glioblastoma
Interventions
Vorinostat, Bevacizumab, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 20, 2026, 10:10 PM EDT
Withdrawn Not applicable Interventional

Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography

NCT05516485
View directory record Official record
Conditions
Brain Neoplasm
Interventions
Assessment, Magnetic Resonance Elastography
Other · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 20, 2026, 10:10 PM EDT
Completed No phase listed Observational

Assessment of Cancer Related Brain Fog Using the Test of Strategic Learning

NCT05519774
View directory record Official record
Conditions
Brain Fog
Interventions
Not listed
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

O(6)-Benzylguanine in Treating Patients With Malignant Glioma

NCT00002971
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

NCT02039947
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

NCT00805376
View directory record Official record
Conditions
Brain Cancer, Central Nervous System Diseases
Interventions
DNX-2401, Tumor Removal
Drug · Procedure
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 20, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

NCT01814813
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
Interventions
HSPPC-96, bevacizumab
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
417
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 20, 2026, 10:10 PM EDT
Recruiting Early Phase 1 Interventional

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

NCT07460232
View directory record Official record
Conditions
Cushing Disease, Pituitary Adenoma
Interventions
Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 10:10 PM EDT
Not yet recruiting Phase 1 Interventional

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

NCT07454668
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic
Interventions
Trastuzumab Deruxtecan, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

NCT00070096
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

NCT03150862
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Pamiparib, TMZ, Radiation
Drug · Radiation
Lead sponsor
BeiGene USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 20, 2026, 10:10 PM EDT
Recruiting Phase 1 Interventional

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NCT03911388
View directory record Official record
Conditions
Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
G207
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months to 22 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 20, 2026, 10:10 PM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Interventions
HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Bakersfield, California • La Jolla, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 20, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

NCT00003484
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6
Drug · Procedure · Radiation
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 20, 2026, 10:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

NCT04528680
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
Interventions
Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
Device · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

NCT01986348
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Selinexor
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 20, 2026, 10:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

NCT00788125
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 20, 2026, 10:10 PM EDT
Terminated Phase 1 Interventional

Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

NCT00895960
View directory record Official record
Conditions
Glioblastoma, CNS Disease, Brain Diseases
Interventions
Dasatinib, RT (Radiotherapy), TMZ (Temozolomide)
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 20, 2026, 10:10 PM EDT
Terminated Phase 1 Interventional

An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

NCT00880061
View directory record Official record
Conditions
Brain Neoplasm, Glioma
Interventions
IL13-PE38QQR
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Up to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 20, 2026, 10:10 PM EDT
Not listed Not applicable Interventional

Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures

NCT02777060
View directory record Official record
Conditions
Diabetes, Cancer, Multiple Sclerosis, Arthritis, Parkinson's Disease, Cognitive Disorders, Brain Injury, Stroke
Interventions
Exergame, Home based balance training
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 20, 2026, 10:10 PM EDT